Investment Rating - The report maintains a "Buy" rating for the company [1][10]. Core Insights - The company’s IF brand has shown strong growth in 2025, while the Innococo brand has faced significant challenges. It is expected that Innococo will return to a positive trajectory in 2026, justifying the "Buy" rating [2][10]. - Revenue for 2025 is projected at $176.4 million, reflecting a year-over-year increase of 11.89%. However, profit margins have been pressured due to currency fluctuations and one-time expenses, leading to a net profit of $22.77 million, down 31.66% year-over-year [10]. - The IF brand has performed well, with a revenue increase of 26.95% to $167 million, significantly outpacing industry averages. The coconut water segment is expected to maintain good growth prospects [10]. - The international market has shown promising results, with revenue growth exceeding 150% in Australia and approximately doubling in the Philippines and Laos. The company plans to continue expanding its distribution network, particularly in high-consumption markets like Australia and Indonesia [10]. Financial Summary - Revenue projections (in million USD) are as follows: 2024A: 157.65, 2025A: 176.40, 2026E: 211.62, 2027E: 249.60, 2028E: 286.89, with growth rates of 80.3%, 11.9%, 20.0%, 17.9%, and 14.9% respectively [4]. - Net profit projections (in million USD) are: 2024A: 33.32, 2025A: 22.77, 2026E: 31.71, 2027E: 40.36, 2028E: 51.78, with year-over-year changes of 98.9%, -31.7%, 39.3%, 27.3%, and 28.3% respectively [4]. - The company’s PE ratio is projected to decrease from 11.44 in 2024A to 7.36 in 2028E, indicating an improving valuation over time [4]. Market Data - The current stock price is HKD 11.65, with a market capitalization of HKD 3,179 million and a 52-week price range of HKD 10.49 to 47.55 [1][7].

IF 继续强劲，INNOCOCO 短期调整 IFBH(6603) IFBH（6603）年报点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | [Table_Invest] 评级： | 增持 | | --- | --- | --- | --- | --- | --- | | 訾猛(分析师) | 021-38676442 | zimeng@gtht.com | S0880513120002 | | | | 颜慧菁(分析师) | 021-23183952 | yanhuijing@gtht.com | S0880525040022 | [当前价格 Table_CurPrice] (港元)： | 11.65 | | 张宇轩(分析师) | 021-23154172 | zhangyuxuan@gtht.com | S0880525040039 | | | 本报告导读： 公司 25 年 if 品牌保持强劲增长，但是 innococo 品牌拖累较大。预计 26年有望重回 良性轨道，维持增持评级。 投资要点： | 财务摘要(百万美元) | 2024A | 2025A | 2026E | 202 ...

Group 1 - The core point of the announcement is that for the fiscal year 2025, the group recorded total revenue of $176.4 million, representing an annual growth of 11.9%, primarily driven by the strong performance of the if brand, which saw a revenue increase of 27%, significantly exceeding the industry average [1][1][1] - Despite the strong growth of the if brand, Innococo's annual performance was severely impacted, with a decline of 63%. This decline was attributed to operational issues rather than a lack of product demand, including internal distributor problems and delays in launching a new sports drink, which had a significant impact in the second half of the year, where Innococo's revenue fell by over 90% [1][1][1] - The group has taken decisive corrective measures to address the issues faced by Innococo and is confident that it will return to a growth trajectory in the coming year [1][1][1] Group 2 - The adjusted profit for the fiscal year 2025 (non-IFRS measure), excluding one-time listing-related professional fees, was $26.9 million, reflecting a year-on-year decline of 22.0%. This decline was mainly due to the temporary operational difficulties faced by Innococo and foreign exchange impacts leading to a decrease in gross margin, as well as strategic marketing investments made for Innococo, including appointing a new brand ambassador and launching promotional activities [1][1][1]

Core Viewpoint - The article highlights the strong performance of IFBH, a well-known consumer company, in the recent IPO market, with a significant increase in its stock price, while the other two companies, Taide Pharmaceutical and Yunzhisheng, showed modest performance [1][21]. Group 1: IFBH Performance - IFBH's stock price surged over 60% in the dark market, making it the biggest winner among the three newly listed companies [1]. - The company achieved a subscription multiple of 2240 times, with a financing subscription amount reaching 2594.8 billion HKD [3][11]. - IFBH has a market share of approximately 34% in the coconut water beverage market in mainland China, leading the market for five consecutive years [12][16]. Group 2: Company Overview - IFBH, founded in 2013, specializes in ready-to-drink beverages and ready-to-eat foods, particularly coconut water, and is a leader in the Chinese market [11]. - The company operates on a light asset model, relying on third-party manufacturers for production, with only 46 employees as of the end of 2024 [12][13]. - IFBH's gross profit margin improved from 34.7% in 2023 to 36.7% in 2024, and its net profit margin increased from 19.2% to 21.1% during the same period [16][17]. Group 3: Competitors' Performance - Taide Pharmaceutical, a global leader in peptide-focused CRDMO, holds a market share of 1.5% and provides comprehensive services from early discovery to commercial production [21]. - Yunzhisheng, an AI solutions provider, ranks as the fourth largest AI solution provider in China with a market share of 0.6%, focusing on conversational AI products for daily life and medical applications [22][23]. - Both Taide Pharmaceutical and Yunzhisheng exhibited lackluster performance in the dark market, contrasting sharply with IFBH's success [1][21].